DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy.
Ma Z, Zhou Z, Duan W, Yao G, Sheng S, Zong S, Zhang X, Li C, Liu Y, Ou F, Dahar MR, Huang Y, Yu L.
Ma Z, et al. Among authors: ou f.
Cancer Immunol Immunother. 2024 Mar 30;73(5):82. doi: 10.1007/s00262-024-03673-x.
Cancer Immunol Immunother. 2024.
PMID: 38554200
Free PMC article.